Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
40S ribosomal protein S29 (RPS29) is a structural component of the 40S small ribosomal subunit, encoded by the RPS29 gene on chromosome 14[1][2][4]. It contains a C2–C2 zinc finger-like domain important for zinc binding and the integrity of the ribosome[2][3][6]. This protein is required for proper ribosomal assembly and efficient protein synthesis within the cytoplasm[2][3][5]. RPS29 can enhance the tumor suppressor activity of Ras-related protein 1A (KREV1)[2][3][5]. Mutations in RPS29 are causative for Diamond-Blackfan anemia subtype 13, a rare congenital erythroid aplasia; altered expression has been observed in some cancers, though its expression level does not correlate with disease severity[1][2][3]. RPS29 is not known to be a direct therapeutic target or to interact with drugs, and no known biomarkers or direct safety concerns have been recorded.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 40S ribosomal protein S29 (RPS29).